The study of the domestic market of antiviral drugs for the pharmacotherapy of complicated influenza in Ukraine

Authors

DOI:

https://doi.org/10.24959/nphj.26.207

Keywords:

complicated form of influenza; antiviral drugs; neuraminidase inhibitors; economic availability; import dependence.

Abstract

Aim. To study the domestic market of antiviral drugs – neuraminidase inhibitors, which are recommended by the clinical treatment protocols for the pharmacotherapy of patients with complicated forms of influenza; to determine their cost aspects and accessibility for the patient.

Materials and methods. The normative and legislative acts and sources of scientific literature on the pharmaceutical component of the treatment of complicated forms of influenza using antiviral drugs, neuraminidase inhibitors (ATC code J05A H), in Ukraine were reviewed. The pharmaceutical market of Ukraine was analyzed in terms of the availability and accessibility of this group of drugs to the population.

Results. Among acute respiratory viral infections, influenza is a key disease among the population in terms of the number of reported cases, severe complications and disability. Severe forms of influenza require inpatient treatment of patients using antiviral drugs. According to the clinical treatment protocol and the WHO recommendations, it is recommended to use neuraminidase inhibitors (J05A H), including Oseltamivir, Zanamivir, Laninavir and Piramivir with the activity against various strains of the influenza virus, for the pharmacotherapy of complicated forms of influenza. Neuraminidase inhibitors are represented in the domestic pharmaceutical market of Ukraine by 15 trade names of foreign manufacturers, which indicates complete import dependence and requires the development and introduction of domestic antiviral drugs into production.

Conclusions. Severe forms of influenza can lead to significant complications of the patient’s disease, and, therefore, the use of neuraminidase inhibitors should prevent the occurrence of severe pathological changes in the patient’s body. The most affordable drug for the patient is Oseltamivir, 75 mg, No. 10 manufactured by Strides India, the course of treatment for which in 2026 will be 5 % of the patient’s minimum wage.

 

References

  1. Shchorichnyi zvit pro stan zdorovia naselennia Ukrainy ta epidemichnu sytuatsiiu za 2022 rik. https://surl.lt/gtvllb
  2. Holubovska, O. A. (2016, Sichen 28). Hryp. Osoblyvosti klinichnoho perebihu ta standarty nadannia medychnoi dopomohy v Ukraini. Natsionalnyi medychnyi universytet imeni O. O. Bohomoltsia. https://nmuofficial.com/news/vazhlyvo-pro-gryp-profesor-olga-golubovska-2/
  3. Uyeki, T. M., Hui, D. S., Zambon, M., Wentworth, D. E., & Monto, A. S. (2022). Influenza. Lancet, 400(10353). 693–706. https://doi.org/10.1016/S0140-6736(22)00982-5
  4. Influenza (seasonal). (2025, February 28). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
  5. Krammer, F., Smith, G. J. D,. Fouchier, R. A. M., Peiris, M., Kedzierska, K., Doherty, P. C., Palese, P., Shaw, M. L., Treanor, J., Webster, R. G., & García-Sastre, A. (2018). Influenza. Nat. Rev. Dis. Primers, 4(1), 3. https://doi.org/10.1038/s41572-018-0002-y
  6. Nakaz MOZ Ukrainy «Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry hrypi ta hostrykh respiratornykh infektsiiakh» № 499 (2014, Lypen 16). https://ips.ligazakon.net/document/MOZ23599
  7. Batool, S., Chokkakula, S., & Song, M. S. (2023). Influenza Treatment: Limitations of Antiviral Therapy and Advantages of Drug Combination Therapy. Microorganisms, 11(1), 183. https://doi.org/10.3390/microorganisms11010183
  8. De Clercq, E. (2006). Antiviral agents active against influenza A viruses. Nat. Rev. Drug. Discov., 5(12), 1015–1025 https://doi.org/10.1038/nrd2175
  9. Gao, Y., Guyatt, G., Uyeki, T. M., Liu, M., Chen, Y., Zhao, Y., Shen, Y., Xu, J., Zheng, Q., Li, Z., Zhao, W., Luo, S., Chen, X., Tian, J., & Hao, Q. (2024). Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. The Lancet, 404(10454), 753–763. https://doi.org/10.1016/S0140-6736(24)01307-2
  10. Mishin, V. P., Hayden, F. G., & Gubareva, L. V. (2005). Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob. Agents Chemother, 49(11), 4515–4520. https://doi.org/ 10.1128 / AAC. 49.11.4515-4520.2005
  11. Hryp ta hostri respiratorni infektsii. (2019, Lystopad 29). DETs MOZ Ukrainy. https://www.dec.gov.ua/mtd/gryp-ta-gostri-respiratorni-infekcziyi/
  12. Groeneveld, G. H., Marbus, S. D., Ismail, N., de Vries, J. J. C., Schneeberger, P., Oosterheert, J. J., van Dissel, J. T., & de Boer, M. G. J. (2020). Effectiveness of oseltamivir in reduction of complications and 30-day mortality in severe seasonal influenza infection. Int. J. Antimicrob. Agents, 56(5), 106155. https://doi.org/ 10.1016/j.ijantimicag.2020.106155
  13. Derzhavnyi reiestr likarskykh zasobiv Ukrainy. http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument&sklad=%CF%B3%F0%E0%EC%B3%E2%B3%F0
  14. Tabletki.ua: ofitsiinyi sait. https://tabletki.ua/
  15. Zakon Ukrainy «Pro Derzhavnyi biudzhet Ukrainy na 2026 rik» № 4695-IX (2025, Hruden 3). https://surl.li/ufzwps

Downloads

Published

2026-03-31

Issue

Vol. 111 No. 1 (2026): News of Pharmacy

Section

Articles

License

Copyright (c) 2026 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.